DPI Media
Stay updated with our latest news and media
Fexuprazan IIT Wrap Up Meeting
Writer
Manager
August 4, 2025
Fexuprazan, our next-generation P-CAB, demonstrated superior efficacy and safety in Investigator-Initiated Trial (IIT) conducted by the Indonesian Society of Gastroenterology, delivering faster relief from GERD symptoms such as heartburn and nausea—outperforming esomeprazole within the first week of treatment.
With global expansion over 30 countries, we are advancing GERD therapy in Indonesia and beyond.
Watch the full feature on RCTI TV to see how our innovation is enhancing patient quality of life.